Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 78

1.

Dynamics of Tissue-Specific CD8+ T Cell Responses during West Nile Virus Infection.

Aguilar-Valenzuela R, Netland J, Seo YJ, Bevan MJ, Grakoui A, Suthar MS.

J Virol. 2018 Apr 27;92(10). pii: e00014-18. doi: 10.1128/JVI.00014-18. Print 2018 May 15.

2.

Alterations in Intestinal Microbiota Lead to Production of Interleukin 17 by Intrahepatic γδ T-Cell Receptor-Positive Cells and Pathogenesis of Cholestatic Liver Disease.

Tedesco D, Thapa M, Chin CY, Ge Y, Gong M, Li J, Gumber S, Speck P, Elrod EJ, Burd EM, Kitchens WH, Magliocca JF, Adams AB, Weiss DS, Mohamadzadeh M, Grakoui A.

Gastroenterology. 2018 Jun;154(8):2178-2193. doi: 10.1053/j.gastro.2018.02.019. Epub 2018 Feb 15.

PMID:
29454797
3.

EphB2 receptor tyrosine kinase promotes hepatic fibrogenesis in mice via activation of hepatic stellate cells.

Mimche PN, Lee CM, Mimche SM, Thapa M, Grakoui A, Henkemeyer M, Lamb TJ.

Sci Rep. 2018 Feb 7;8(1):2532. doi: 10.1038/s41598-018-20926-9.

4.

Of mice, rats, and men: Small animal model of hepatitis C virus infection.

Grakoui A, Walker CM.

Hepatology. 2018 Jul;68(1):374-376. doi: 10.1002/hep.29765. Epub 2018 May 9. No abstract available.

5.

Environmental peer pressure: CD4+ T cell help in tolerance and transplantation.

Tedesco D, Grakoui A.

Liver Transpl. 2018 Jan;24(1):89-97. doi: 10.1002/lt.24873. Review.

6.

Local Cellular and Cytokine Cues in the Spleen Regulate In Situ T Cell Receptor Affinity, Function, and Fate of CD8+ T Cells.

Seo YJ, Jothikumar P, Suthar MS, Zhu C, Grakoui A.

Immunity. 2016 Nov 15;45(5):988-998. doi: 10.1016/j.immuni.2016.10.024.

7.

Novel E2 Glycoprotein Tetramer Detects Hepatitis C Virus-Specific Memory B Cells.

Boisvert M, Zhang W, Elrod EJ, Bernard NF, Villeneuve JP, Bruneau J, Marcotrigiano J, Shoukry NH, Grakoui A.

J Immunol. 2016 Dec 15;197(12):4848-4858. Epub 2016 Nov 14.

8.

CD4+ Foxp3+ T cells promote aberrant immunoglobulin G production and maintain CD8+ T-cell suppression during chronic liver disease.

Tedesco D, Thapa M, Gumber S, Elrod EJ, Rahman K, Ibegbu CC, Magliocca JF, Adams AB, Anania F, Grakoui A.

Hepatology. 2017 Feb;65(2):661-677. doi: 10.1002/hep.28894. Epub 2016 Dec 19.

9.

Future landscape of hepatitis C research - Basic, translational and clinical perspectives.

Moradpour D, Grakoui A, Manns MP.

J Hepatol. 2016 Oct;65(1 Suppl):S143-S155. doi: 10.1016/j.jhep.2016.07.026. Review.

PMID:
27641984
10.

Prolonged activation of innate antiviral gene signature after childbirth is determined by IFNL3 genotype.

Price AA, Tedesco D, Prasad MR, Workowski KA, Walker CM, Suthar MS, Honegger JR, Grakoui A.

Proc Natl Acad Sci U S A. 2016 Sep 20;113(38):10678-83. doi: 10.1073/pnas.1602319113. Epub 2016 Sep 6.

11.

Influence of IFNL3 and HLA-DPB1 genotype on postpartum control of hepatitis C virus replication and T-cell recovery.

Honegger JR, Tedesco D, Kohout JA, Prasad MR, Price AA, Lindquist T, Ohmer S, Moore-Clingenpeel M, Grakoui A, Walker CM.

Proc Natl Acad Sci U S A. 2016 Sep 20;113(38):10684-9. doi: 10.1073/pnas.1602337113. Epub 2016 Sep 6.

12.

Presentation of hepatocellular antigens.

Grakoui A, Crispe IN.

Cell Mol Immunol. 2016 May;13(3):293-300. doi: 10.1038/cmi.2015.109. Epub 2016 Feb 29. Review.

13.

Harnessing the Prokaryotic Adaptive Immune System as a Eukaryotic Antiviral Defense.

Price AA, Grakoui A, Weiss DS.

Trends Microbiol. 2016 Apr;24(4):294-306. doi: 10.1016/j.tim.2016.01.005. Epub 2016 Feb 3. Review.

14.

Hepatitis C virus: why do we need a vaccine to prevent a curable persistent infection?

Walker CM, Grakoui A.

Curr Opin Immunol. 2015 Aug;35:137-43. doi: 10.1016/j.coi.2015.06.010. Epub 2015 Aug 1. Review.

15.

IFN-α-Induced Downregulation of miR-221 in Dendritic Cells: Implications for HCV Pathogenesis and Treatment.

Sehgal M, Zeremski M, Talal AH, Ginwala R, Elrod E, Grakoui A, Li QG, Philip R, Khan ZK, Jain P.

J Interferon Cytokine Res. 2015 Sep;35(9):698-709. doi: 10.1089/jir.2014.0211. Epub 2015 Jun 19.

16.

Cas9-mediated targeting of viral RNA in eukaryotic cells.

Price AA, Sampson TR, Ratner HK, Grakoui A, Weiss DS.

Proc Natl Acad Sci U S A. 2015 May 12;112(19):6164-9. doi: 10.1073/pnas.1422340112. Epub 2015 Apr 27.

17.

Pillars article: The immunological synapse: a molecular machine controlling T cell activation. Science. 1999. 285: 221-227.

Grakoui A, Bromley SK, Sumen C, Davis MM, Shaw AS, Allen PM, Dustin ML.

J Immunol. 2015 May 1;194(9):4066-72. No abstract available.

18.

The receptor tyrosine kinase EphB2 promotes hepatic fibrosis in mice.

Mimche PN, Brady LM, Bray CF, Lee CM, Thapa M, King TP, Quicke K, McDermott CD, Mimche SM, Grakoui A, Morgan ET, Lamb TJ.

Hepatology. 2015 Sep;62(3):900-14. doi: 10.1002/hep.27792. Epub 2015 Apr 22.

19.

Liver fibrosis occurs through dysregulation of MyD88-dependent innate B-cell activity.

Thapa M, Chinnadurai R, Velazquez VM, Tedesco D, Elrod E, Han JH, Sharma P, Ibegbu C, Gewirtz A, Anania F, Pulendran B, Suthar MS, Grakoui A.

Hepatology. 2015 Jun;61(6):2067-79. doi: 10.1002/hep.27761. Epub 2015 Mar 25.

20.

Systems biological analyses reveal the hepatitis C virus (HCV)-specific regulation of hematopoietic development.

Velazquez VM, Uebelhoer LS, Thapa M, Ibegbu CC, Courtney C, Bosinger SE, Magliocca JF, Adams AB, Kirk AD, Knechtle SJ, Kalman D, Suthar MS, Grakoui A.

Hepatology. 2015 Mar;61(3):843-56. doi: 10.1002/hep.27575. Epub 2015 Jan 30.

21.

HCV adaptations to altered CD8+ T-cell immunity during pregnancy.

Price AA, Grakoui A, Honegger JR.

Future Virol. 2014 Apr 1;9(4):333-336. No abstract available.

22.

Structure of the core ectodomain of the hepatitis C virus envelope glycoprotein 2.

Khan AG, Whidby J, Miller MT, Scarborough H, Zatorski AV, Cygan A, Price AA, Yost SA, Bohannon CD, Jacob J, Grakoui A, Marcotrigiano J.

Nature. 2014 May 15;509(7500):381-4. doi: 10.1038/nature13117. Epub 2014 Feb 19.

23.

A neutralization epitope in the hepatitis C virus E2 glycoprotein interacts with host entry factor CD81.

Zhao Z, Zhong L, Elrod E, Struble E, Ma L, Yan H, Harman C, Deng L, Virata-Theimer ML, Liu P, Alter H, Grakoui A, Zhang P.

PLoS One. 2014 Jan 6;9(1):e84346. doi: 10.1371/journal.pone.0084346. eCollection 2014.

24.

Loss of immune escape mutations during persistent HCV infection in pregnancy enhances replication of vertically transmitted viruses.

Honegger JR, Kim S, Price AA, Kohout JA, McKnight KL, Prasad MR, Lemon SM, Grakoui A, Walker CM.

Nat Med. 2013 Nov;19(11):1529-33. doi: 10.1038/nm.3351. Epub 2013 Oct 27.

25.

Immunotherapy of chronic hepatitis C virus infection with antibodies against programmed cell death-1 (PD-1).

Fuller MJ, Callendret B, Zhu B, Freeman GJ, Hasselschwert DL, Satterfield W, Sharpe AH, Dustin LB, Rice CM, Grakoui A, Ahmed R, Walker CM.

Proc Natl Acad Sci U S A. 2013 Sep 10;110(37):15001-6. doi: 10.1073/pnas.1312772110. Epub 2013 Aug 26.

26.

Chronic but not acute virus infection induces sustained expansion of myeloid suppressor cell numbers that inhibit viral-specific T cell immunity.

Norris BA, Uebelhoer LS, Nakaya HI, Price AA, Grakoui A, Pulendran B.

Immunity. 2013 Feb 21;38(2):309-21. doi: 10.1016/j.immuni.2012.10.022.

27.

Hepatic stellate cells preferentially induce Foxp3+ regulatory T cells by production of retinoic acid.

Dunham RM, Thapa M, Velazquez VM, Elrod EJ, Denning TL, Pulendran B, Grakoui A.

J Immunol. 2013 Mar 1;190(5):2009-16. doi: 10.4049/jimmunol.1201937. Epub 2013 Jan 28.

28.

Structural and functional insights into alphavirus polyprotein processing and pathogenesis.

Shin G, Yost SA, Miller MT, Elrod EJ, Grakoui A, Marcotrigiano J.

Proc Natl Acad Sci U S A. 2012 Oct 9;109(41):16534-9. doi: 10.1073/pnas.1210418109. Epub 2012 Sep 25.

29.

Immune quiescence and hepatitis B virus: tolerance has its limits.

Velazquez VM, Grakoui A.

Gastroenterology. 2012 Sep;143(3):529-532. doi: 10.1053/j.gastro.2012.07.089. Epub 2012 Jul 27. No abstract available.

PMID:
22841510
30.

Hepatic enrichment and activation of myeloid dendritic cells during chronic hepatitis C virus infection.

Velazquez VM, Hon H, Ibegbu C, Knechtle SJ, Kirk AD, Grakoui A.

Hepatology. 2012 Dec;56(6):2071-81. doi: 10.1002/hep.25904.

31.

Hepatic transplant and HCV: a new playground for an old virus.

Chinnadurai R, Velazquez V, Grakoui A.

Am J Transplant. 2012 Feb;12(2):298-305. doi: 10.1111/j.1600-6143.2011.03812.x. Epub 2011 Nov 1. Review.

32.

Hepatitis C virus is primed by CD81 protein for low pH-dependent fusion.

Sharma NR, Mateu G, Dreux M, Grakoui A, Cosset FL, Melikyan GB.

J Biol Chem. 2011 Sep 2;286(35):30361-76. doi: 10.1074/jbc.M111.263350. Epub 2011 Jul 7.

33.

A spatial view of the CD8+ T-cell response: the case of HCV.

Racanelli V, Leone P, Grakoui A.

Rev Med Virol. 2011 Nov;21(6):347-57. doi: 10.1002/rmv.702. Epub 2011 Jul 5. Review.

34.

B7-H4 mediates inhibition of T cell responses by activated murine hepatic stellate cells.

Chinnadurai R, Grakoui A.

Hepatology. 2010 Dec;52(6):2177-85. doi: 10.1002/hep.23953. Epub 2010 Nov 9.

35.

Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway.

Gupta NA, Mells J, Dunham RM, Grakoui A, Handy J, Saxena NK, Anania FA.

Hepatology. 2010 May;51(5):1584-92. doi: 10.1002/hep.23569.

36.

Transient CD86 expression on hepatitis C virus-specific CD8+ T cells in acute infection is linked to sufficient IL-2 signaling.

Radziewicz H, Ibegbu CC, Hon H, Bédard N, Bruneau J, Workowski KA, Knechtle SJ, Kirk AD, Larsen CP, Shoukry NH, Grakoui A.

J Immunol. 2010 Mar 1;184(5):2410-22. doi: 10.4049/jimmunol.0902994. Epub 2010 Jan 25.

37.

Acute hepatitis C and HIV coinfection.

Dionne-Odom J, Osborn MK, Radziewicz H, Grakoui A, Workowski K.

Lancet Infect Dis. 2009 Dec;9(12):775-83. doi: 10.1016/S1473-3099(09)70264-6. Review.

PMID:
19926037
38.

Blocking hepatitis C virus infection with recombinant form of envelope protein 2 ectodomain.

Whidby J, Mateu G, Scarborough H, Demeler B, Grakoui A, Marcotrigiano J.

J Virol. 2009 Nov;83(21):11078-89. doi: 10.1128/JVI.00800-09. Epub 2009 Aug 26.

39.

Roles for endocytic trafficking and phosphatidylinositol 4-kinase III alpha in hepatitis C virus replication.

Berger KL, Cooper JD, Heaton NS, Yoon R, Oakland TE, Jordan TX, Mateu G, Grakoui A, Randall G.

Proc Natl Acad Sci U S A. 2009 May 5;106(18):7577-82. doi: 10.1073/pnas.0902693106. Epub 2009 Apr 17.

40.

PD-1 tempers Tregs in chronic HCV infection.

Radziewicz H, Dunham RM, Grakoui A.

J Clin Invest. 2009 Mar;119(3):450-3.

41.

Rare birds in North America: acute hepatitis C cohorts.

Cox AL, Page K, Bruneau J, Shoukry NH, Lauer GM, Kim AY, Rosen HR, Radziewicz H, Grakoui A, Fierer DS, Branch AD, Kaplan DE, Chang KM.

Gastroenterology. 2009 Jan;136(1):26-31. doi: 10.1053/j.gastro.2008.11.049. Epub 2008 Dec 4. No abstract available.

42.

Stable cytotoxic T cell escape mutation in hepatitis C virus is linked to maintenance of viral fitness.

Uebelhoer L, Han JH, Callendret B, Mateu G, Shoukry NH, Hanson HL, Rice CM, Walker CM, Grakoui A.

PLoS Pathog. 2008 Sep 5;4(9):e1000143. doi: 10.1371/journal.ppat.1000143.

43.

Impaired hepatitis C virus (HCV)-specific effector CD8+ T cells undergo massive apoptosis in the peripheral blood during acute HCV infection and in the liver during the chronic phase of infection.

Radziewicz H, Ibegbu CC, Hon H, Osborn MK, Obideen K, Wehbi M, Freeman GJ, Lennox JL, Workowski KA, Hanson HL, Grakoui A.

J Virol. 2008 Oct;82(20):9808-22. doi: 10.1128/JVI.01075-08. Epub 2008 Jul 30.

44.

Differential expression of CD26 on virus-specific CD8(+) T cells during active, latent and resolved infection.

Ibegbu CC, Xu YX, Fillos D, Radziewicz H, Grakoui A, Kourtis AP.

Immunology. 2009 Mar;126(3):346-53. doi: 10.1111/j.1365-2567.2008.02899.x. Epub 2008 Jul 22.

45.

Unraveling the role of PD-1/PD-L interactions in persistent hepatotropic infections: potential for therapeutic application?

Radziewicz H, Hanson HL, Ahmed R, Grakoui A.

Gastroenterology. 2008 Jun;134(7):2168-71. doi: 10.1053/j.gastro.2008.04.012. Epub 2008 May 16. No abstract available.

PMID:
18486616
46.

Intragenotypic JFH1 based recombinant hepatitis C virus produces high levels of infectious particles but causes increased cell death.

Mateu G, Donis RO, Wakita T, Bukh J, Grakoui A.

Virology. 2008 Jul 5;376(2):397-407. doi: 10.1016/j.virol.2008.03.027. Epub 2008 May 2.

47.

Variable patterns of programmed death-1 expression on fully functional memory T cells after spontaneous resolution of hepatitis C virus infection.

Bowen DG, Shoukry NH, Grakoui A, Fuller MJ, Cawthon AG, Dong C, Hasselschwert DL, Brasky KM, Freeman GJ, Seth NP, Wucherpfennig KW, Houghton M, Walker CM.

J Virol. 2008 May;82(10):5109-14. doi: 10.1128/JVI.00060-08. Epub 2008 Mar 12.

48.

Memory CD8+ T cell differentiation in viral infection: a cell for all seasons.

Radziewicz H, Uebelhoer L, Bengsch B, Grakoui A.

World J Gastroenterol. 2007 Sep 28;13(36):4848-57. Review.

49.

Evidence for a functional RNA element in the hepatitis C virus core gene.

McMullan LK, Grakoui A, Evans MJ, Mihalik K, Puig M, Branch AD, Feinstone SM, Rice CM.

Proc Natl Acad Sci U S A. 2007 Feb 20;104(8):2879-84. Epub 2007 Feb 13.

50.

Liver-infiltrating lymphocytes in chronic human hepatitis C virus infection display an exhausted phenotype with high levels of PD-1 and low levels of CD127 expression.

Radziewicz H, Ibegbu CC, Fernandez ML, Workowski KA, Obideen K, Wehbi M, Hanson HL, Steinberg JP, Masopust D, Wherry EJ, Altman JD, Rouse BT, Freeman GJ, Ahmed R, Grakoui A.

J Virol. 2007 Mar;81(6):2545-53. Epub 2006 Dec 20.

Supplemental Content

Loading ...
Support Center